Edmond de Rothschild Corporate Finance has advised Ardian on the acquisition of Unither alongside management - Pending

Corporate Finance - 11/18/2016

Ardian has announces that it has submitted a binding offer and has entered into exclusive negotiations with Equistone, leading a consortium including in particular the historic shareholders Parquest Capital and CM-CIC Investissement to acquire their majority stake in Unither, a world-leading Contract Development and Manufacturing Organization (CDMO) in single unit dosage forms. The management team, led by Eric Goupil, Group CEO, will reinvest significantly in the company.

Unither Pharmaceuticals, has become a globally renowned company for the development and manufacturing of sterile unit-doses, non-sterile liquids, liquid sticks, solid and semi-solid medications for the pharmaceutical and generic drug industry. The company operates 6 manufacturing sites and 1 R&D center in France, USA and Brazil. Founded in 1993 from the takeover of a Sanofi facility, Unither Pharmaceuticals generates revenues of +250 M€ with a team of more than 1,200 professionals. The Group offers a comprehensive range of products and is the world largest player in blow-fill-seal (BFS) sterile unit-dose market. Unither has been the trusted partner of several medium to large pharmaceutical companies for many years thanks to its long-standing track record of quality, innovation and industrial excellence.

The transaction will be put before the Unither Work Council and is subject to the signing of a definitive agreement, as well as the approval of the relevant competition and regulatory authorities.

Edmond de Rothschild Corporate Finance
M&A: Christian Menard (Managing director, member of the board), Laure Klein (Vice-president), Arthur Pignot (Analyst), Mohamed Rtel Bennani (Analyst)

Elément complémentaire


Need more information ?

Contact us


47 rue du Faubourg Saint-Honoré
75401 Cedex 08
Paris

+ 33 1 40 17 25 25